Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), Enduser (Hospital, ASC) - Global Industry Analysis, Share ,Growth ,Regional Outlook And Forecasts, 2021-2027
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Interventional Oncology Market, By Product
7.1. Interventional Oncology Market, By Product, 2020-2027
7.1.1. Embolization Devices
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Ablation Devices
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Support Devices
7.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Interventional Oncology Market, By Procedure
8.1. Interventional Oncology Market, By Procedure, 2020-2027
8.1.1. Thermal Tumor Ablation
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Non-Thermal Tumor Ablation
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Transcatheter Arterial Chemoembolization
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. Transcatheter Arterial Embolization/Bland Embolization
8.1.5.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Interventional Oncology Market, By Cancer Type
9.1. Interventional Oncology Market, By Cancer Type, 2020-2027
9.1.1. Liver Cancer
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Bone Metastasis
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Kidney Cancer
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Breast Cancer
9.1.5.1. Market Revenue and Forecast (2016-2027)
9.1.6. Breast Cancer
9.1.6.1. Market Revenue and Forecast (2016-2027)
9.1.7. Other Cancers
9.1.7.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Interventional Oncology Market, By End Users
10.1. Interventional Oncology Market, By End Users, 2020-2027
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Ambulatory Surgery Centers
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Research & Academic Institutes
10.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 11.Global Interventional Oncology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, By Product (2016-2027)
11.1.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.1.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.1.4. Market Revenue and Forecast, By End Users (2016-2027)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, By Product (2016-2027)
11.1.5.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.1.5.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.1.5.4. Market Revenue and Forecast, By End Users (2016-2027)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, By Product (2016-2027)
11.1.6.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.1.6.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.1.6.4. Market Revenue and Forecast, By End Users (2016-2027)
11.2. Europe
11.2.1. Market Revenue and Forecast, By Product (2016-2027)
11.2.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.2.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.2.4. Market Revenue and Forecast, By End Users (2016-2027)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, By Product (2016-2027)
11.2.5.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.2.5.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.2.5.4. Market Revenue and Forecast, By End Users (2016-2027)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, By Product(2016-2027)
11.2.6.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.2.6.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.2.6.4. Market Revenue and Forecast, By End Users (2016-2027)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, By Product (2016-2027)
11.2.7.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.2.7.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.2.7.4. Market Revenue and Forecast, By End Users (2016-2027)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, By Product (2016-2027)
11.2.8.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.2.8.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.2.8.4. Market Revenue and Forecast, By End Users (2016-2027)
11.3. APAC
11.3.1. Market Revenue and Forecast, By Product (2016-2027)
11.3.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.3.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.3.4. Market Revenue and Forecast, By End Users (2016-2027)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, By Product (2016-2027)
11.3.5.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.3.5.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.3.5.4. Market Revenue and Forecast, By End Users (2016-2027)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, By Product (2016-2027)
11.3.6.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.3.6.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.3.6.4. Market Revenue and Forecast, By End Users (2016-2027)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, By Product (2016-2027)
11.3.7.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.3.7.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.3.7.4. Market Revenue and Forecast, By End Users (2016-2027)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, By Product (2016-2027)
11.3.8.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.3.8.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.3.8.4. Market Revenue and Forecast, By End Users (2016-2027)
11.4. MEA
11.4.1. Market Revenue and Forecast, By Product (2016-2027)
11.4.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.4.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.4.4. Market Revenue and Forecast, By End Users (2016-2027)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, By Product (2016-2027)
11.4.5.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.4.5.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.4.5.4. Market Revenue and Forecast, By End Users (2016-2027)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, By Product (2016-2027)
11.4.6.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.4.6.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.4.6.4. Market Revenue and Forecast, By End Users (2016-2027)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, By Product (2016-2027)
11.4.7.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.4.7.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.4.7.4. Market Revenue and Forecast, By End Users (2016-2027)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, By Product (2016-2027)
11.4.8.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.4.8.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.4.8.4. Market Revenue and Forecast, By End Users (2016-2027)
11.5. Latin America
11.5.1. Market Revenue and Forecast, By Product (2016-2027)
11.5.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.5.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.5.4. Market Revenue and Forecast, By End Users (2016-2027)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, By Product (2016-2027)
11.5.5.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.5.5.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.5.5.4. Market Revenue and Forecast, By End Users (2016-2027)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, By Product (2016-2027)
11.5.6.2. Market Revenue and Forecast, By Procedure (2016-2027)
11.5.6.3. Market Revenue and Forecast, By Cancer Type (2016-2027)
11.5.6.4. Market Revenue and Forecast, By End Users (2016-2027)
Chapter 12. Company Profiles
12.1. Medtronic (Ireland)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Boston Scientific (US)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. BD (US)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Terumo (Japan)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Merit Medical (US)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AngioDynamics (US)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. J&J (US)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Teleflex (US)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Cook Medical (US)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. HealthTronics (US)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. MedWaves (US), Sanarus (US)
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Trod Medical (US)
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. IceCure Medical (Israel)
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
12.14. Mermaid Medicals (Denmark)
12.14.1. Company Overview
12.14.2. Product Offerings
12.14.3. Financial Performance
12.14.4. Recent Initiatives
12.15. Interface Biomaterials BV (Netherlands)
12.15.1. Company Overview
12.15.2. Product Offerings
12.15.3. Financial Performance
12.15.4. Recent Initiatives
12.16. Guerbet (France)
12.16.1. Company Overview
12.16.2. Product Offerings
12.16.3. Financial Performance
12.16.4. Recent Initiatives
12.17. ABK Biomedical (Canada)
12.17.1. Company Overview
12.17.2. Product Offerings
12.17.3. Financial Performance
12.17.4. Recent Initiatives
12.18. Shape Memory Medical (US)
12.18.1. Company Overview
12.18.2. Product Offerings
12.18.3. Financial Performance
12.18.4. Recent Initiatives
12.19. Endo Shape (US)
12.19.1. Company Overview
12.19.2. Product Offerings
12.19.3. Financial Performance
12.19.4. Recent Initiatives
12.20. Monteris Medical (US)
12.20.1. Company Overview
12.20.2. Product Offerings
12.20.3. Financial Performance
12.20.4. Recent Initiatives
12.21. Instylla (US)
12.21.1. Company Overview
12.21.2. Product Offerings
12.21.3. Financial Performance
12.21.4. Recent Initiatives
12.22. Trisalus Lifesciences (US)
12.22.1. Company Overview
12.22.2. Product Offerings
12.22.3. Financial Performance
12.22.4. Recent Initiatives
12.23. Profound Medical Corp (Canada)
12.23.1. Company Overview
12.23.2. Product Offerings
12.23.3. Financial Performance
12.23.4. Recent Initiatives
12.24. Sirtex (US)
12.24.1. Company Overview
12.24.2. Product Offerings
12.24.3. Financial Performance
12.24.4. Recent Initiatives
12.25. Accuray (US)
12.25.1. Company Overview
12.25.2. Product Offerings
12.25.3. Financial Performance
12.25.4. Recent Initiatives
12.26. Baylis Medical (Canada)
12.26.1. Company Overview
12.26.2. Product Offerings
12.26.3. Financial Performance
12.26.4. Recent Initiatives
12.27. ALPINION MEDICAL SYSTEMS (South Korea)
12.27.1. Company Overview
12.27.2. Product Offerings
12.27.3. Financial Performance
12.27.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms